Novartis | NOVN - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 645M 69M 2026-03
Alcon AG USD 53M 1000K 2026-06
Amgen USD 95.64B 94.98B 2026-06
AstraZeneca USD 340M 144M 2026-06
Autolus Therapeutics Ltd USD 11.12M 11.71M 2026-03
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Fresenius EUR 81M 5M 2025-09
Fresenius Medical Care EUR 83M 4M 2026-06
Genmab DKK 139M 129M 2026-06
Gilead Sciences USD 247M 7M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
GRIFOLS EUR 141.43M 61.28M 2025-06
Hikma Pharmaceutical USD 67M 47M 2025-12
J&J USD 43M 25M 2026-03
Lakefront Biotherapeutics EUR 1.72M 940K 2025-09
Lonza CHF 84M 14M 2025-06
Merck EUR 137M 33M 2026-06
Merck USD 525M 46M 2026-06
Novartis USD 462M 119M 2026-06
Novartis USD 281M 8M 2025-09
Novo Nordisk DKK 1.5B 28M 2026-06
Orion EUR 700K 700K 2026-06
Pfizer USD 667M 4M 2026-06
Philips EUR 83M 26M 2026-03
Recordati EUR 22.13M 1.43M 2025-12
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 287M 109M 2026-06
UCB EUR 49M 29M 2025-12